"10.1371_journal.pone.0101477","plos one","2014-07-02T00:00:00Z","Erin Bargerstock; Vikram Puvenna; Philip Iffland; Tatiana Falcone; Mohammad Hossain; Stephen Vetter; Shumei Man; Leah Dickstein; Nicola Marchi; Chaitali Ghosh; Juliana Carvalho-Tavares; Damir Janigro","Cerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Biomedical Engineering, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Flocel, Inc. Cleveland, Ohio, United States of America; Kent State University, Kent, Ohio, United States of America; Department of Psychiatry, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America","Conceived and designed the experiments: DJ. Performed the experiments: EB VP PI SM MH CG LD JCT SV. Analyzed the data: DJ EB VP CG NM. Contributed reagents/materials/analysis tools: DJ TF. Wrote the paper: DJ EB VP CG.","DJ holds two US patents on the use of S100B as a marker of blood-brain barrier disruption (Markers of Blood Barrier Disruption and Methods of using same -US 7,144,708 and Peripheral Marker of Blood Brain Barrier Permeability-US 6,884,591B2). DJ is employed by Flocel, Inc. Cleveland. DJ received 5 years ago income from a two year license of the S100B technology. The authors are not aware at this time of any organization which may benefit from the publication of this article. No diagnostic or use-related claims or data are contained herein. The Cleveland Clinic policy on Conflict of Interest has established a management plan with NIH guidelines and Cleveland Clinic policies. This does not alter The authors adherence to PLOS ONE policies on sharing data and materials.","2014","07","Erin Bargerstock","EB",12,TRUE,1,9,5,4,TRUE,TRUE,FALSE,0,NA,FALSE
